Back to the main directory
Company Analysis / Equity
- AEMD: Operational Update: Progress on Ebola, U.S. HCV, ESI, Cancer by Zacks
- AEMD: Q1 Results. Add Zika to List of Potential Viral Targets by Zacks
- AEMD: Q4 Results, U.S. Clinical Study Progressing, ATM Financing by Zacks
- AEMD: U.S. HCV Study Kicks Off, Ebola Looks Promising by Zacks
- AEMD: DaVita CR To Manage Clinical Study by Zacks
- Awarded Year-3 DARPA Contract Worth $1.5 Million by Zacks
- APDN: Balance sheet remains strong; we remain optimistic about the company for its long term growth potential by Zacks
- Advaxis ADXS Balance Sheet Remains Strong by Zacks
- Advaxis Reports Encouraging Preliminary Phase II ADXS-HPV Data by Zacks
- DARPA Revenue, Operational Progress Continues by Zacks
- Fiscal 2012 10-K Filed by Zacks
- AEMD: Heading Into FY2016 With Accelerating Momentum by Zacks
- More Encouraging Preliminary Data of Phase II ADXS-HPV Reported by Zacks
- Pipeline further boosted by new indication; Positive results for Cervical Cancer presented by Zacks
- Positive results for CIN and Cervical Cancer presented by Zacks
- Unique Immunotherapy platform by Zacks
- Unique immunotherapy platform technology with middle stage pipeline- maintaining an Outperform rating by Zacks
- Unique immunotherapy platform technology with middle stage pipeline- maintaining an Outperform rating by Zacks
- APDN: 2Q14 revenue increased by 85% yoy, highest revenue for second quarter in the company s history; businesses continue to grow--Outperform by Zacks
- APDN: Price target adjusted to $12 per share reflecting recent reverse stock split; Record revenue reported for fiscal 3Q14 and first nine months of 2014, businesses continue to grow- -Outperform by Zacks
- APDN: Record revenue reported for fiscal 2014, businesses continue to grow. Price target adjusted to $12 per share reflecting recent reverse stock split--Outperform by Zacks
- APDN: Record revenue reported for fiscal 3Q14 and first nine months of 2014, businesses continue to grow--Outperform by Zacks
- APDN Reports Record Revenue by Zacks
- APDN: Revenue continued to grow in fiscal first quarter of 2016, entering diagnostic market, balance sheet boosted, businesses continue to grow--Buy by Zacks
- APDN: 1Q14 revenue increased by 88%, highest revenue for first quarter in the company s history; balance sheet remained strong, businesses continue to grow-- Outperform by Zacks
- AEMD: Operational Update: Progress on Ebola, U.S. HCV, ESI, Cancer by Zacks
- AEMD: Q1 Update, Revived Attention on Ebola by Zacks
- AEMD: U.S. Clinical Study Progressing. Zika Could Offer Another Opportunity by Zacks
- AEMD: Encouraging Meeting With Jim Joyce by Zacks
- Remain Encouraged By Ongoing Progress by Zacks
- AEMD: FDA Study, DARPA Milestones, Productive Operationally by Zacks
- APDN: We remain optimistic about the company for its long term growth potential by Zacks
- Advaxis Completes Pre-IND Meeting for ADXS-HER2 by Zacks
- Big deal secured for ADXS-cHER2 animal health program; Two deals in two months for ADXS-HPV; Balance sheet boosted; On track to advance its pipeline -- Outperform by Zacks
- FDA Answer On IDE Should Be Forthcoming by Zacks
- Fiscal Q1 2013 10-Q Filed by Zacks
- Hitting Milestones, Operational Progress by Zacks
- New financing boosts balance sheet; by Zacks
- Positive clinical results could spike partnership interests by Zacks
- Positive results presented at ASCO by Zacks
- Unique immunotherapy platform technology with middle stage pipeline- initiating with Outperform rating by Zacks
- Unique immunotherapy platform technology with middle stage pipeline- maintaining an Outperform rating by Zacks
- Recent Progress Helps De-Risk AEMD by Zacks
- APDN: Another strong quarter for the three months ended June 30, 2015; balance sheet boosted, businesses continue to grow--Buy by Zacks
- APDN: Record revenue reported for fiscal 1Q15, businesses continue to grow-- Outperform by Zacks
- APDN: Record revenue reported for fiscal 2Q15, balance sheet boosted, businesses continue to grow--Buy by Zacks
- APDN: Reported record revenue for 4Q15 and fiscal year 2015, entering diagnostic market, balance sheet boosted, businesses continue to grow--Buy by Zacks
- APDN Reports Record Revenue by Zacks
- APDN: Second quarter revenue decline disappointing, but remain optimistic for long term growth by Zacks
- Record sales reported in fiscal third quarter and businesses continue to grow by Zacks